Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the  Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfill our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free more...


Article type

Original Article


Article page

240-245


Authors Details

Anand Babu M N, Prashanth C N*, Sribhargava Natesh


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 83

PDF Downloaded: 64


Management of macular edema secondary to branch retinal vein occlusion-combined treatment with intravitreal bevacizumab and ozurdex implant


Original Article

Author Details : Anand Babu M N, Prashanth C N*, Sribhargava Natesh

Volume : 7, Issue : 1, Year : 2021

Article Page : 240-245

https://doi.org/10.18231/j.ijceo.2021.049



Suggest article by email


Abstract

Purpose: To evaluate the efficacy and safety of a dexamethasone implant in combination with intravitreal
bevacizumab injection in the management of macular edema secondary to branch retinal venous occlusion.
Materials and Methods: 10 eyes were prospectively investigated. Each eye was treated with intravitreal
bevacizumab followed by intravitreal ozurdex at a two week interval. Recurrence of macular edema
was treated with ozurdex only. Patient were evaluated preoperatively with BCVA, IOP, OCT and fundus
evaluation and followed up at 15 days, 2months and 4months of ozurdex injection. Fallow up all patient for
1 year duration.
Results: Mean BCVA at presentation was 0.81 log mar, and that improved to after 15 days of intravitreal
bevacizumab was 0.55 log mar. At 15 days, 2 months and 4 months of intravitreal ozurdex implantation
mean BCVA was 0.54logmar, 0.54 log mar and 0.6logmar respectively. Mean central foveal retinal
thickness at presentation was 538 µm and reduced to 235 µm, after intravitreal bevacizumab. At 15 days,
2 months and 4 months after intravitreal ozurdex implantation mean central foveal retinal thickness was
182.14 µm, 189.28 µm and 352.14 µm respectively. Mean Intraocular pressure (IOP) was elevated about 1
mm of Hg after bevacizumab, about 3 mm of Hg after 4 months of ozurdex with using single anti glaucoma
medication and one patient had progression of cataract after 2nd injection of ozurdex.
Conclusion: Combined treatment of intravitreal bevacizumab and ozurdex shows better and a sustained
functional outcome. Increased intraocular pressure and cataract formation can be potential concerns and
should be monitored.

Keywords: Macular edema secondary, Intravitreal bevacizumab, Intravitreal Ozurdex.


How to cite : Anand Babu M N, Prashanth C N, Natesh S, Management of macular edema secondary to branch retinal vein occlusion-combined treatment with intravitreal bevacizumab and ozurdex implant. Indian J Clin Exp Ophthalmol 2021;7(1):240-245

Copyright © 2021 by author(s) and Indian J Clin Exp Ophthalmol. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)